Dataset Information

Future directions in the evaluation of c-MET-driven malignancies.

ABSTRACT: The c-MET (mesenchymal-epithelial transition factor) receptor tyrosine kinase is an exciting novel drug target in view of its key role in oncogenesis, as well as its association with disease prognosis in a number of malignancies. Several drugs targeting c-MET are currently showing promise in clinical trials and will hopefully validate positive observations from preclinical studies. The potential efficacy of these different therapeutic agents is expected to be influenced by the mechanism of aberrant hepatocyte growth factor (HGF)/c-MET signaling pathway activation in a particular cancer, but presents a promising strategy for cancer treatment either as a single agent or as part of a combination therapeutic approach. However, there is an ongoing need to improve and accelerate the transition of preclinical research into improved therapeutic strategies for patients with cancer. The main challenges facing the development of HGF/c-MET-targeted agents for cancer treatment include the discovery of rationally designed anticancer drugs and combination strategies, as well as the validation of predictive biomarkers. This paper discusses these issues, with a particular focus on future directions in the evaluation of c-MET-driven malignancies.

SUBMITTER: de Bono JS

PROVIDER: S-EPMC3225021 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Future directions in the evaluation of c-MET-driven malignancies.

de Bono Johann S JS Yap Timothy A TA

Therapeutic advances in medical oncology 20111101 1 Suppl

The c-MET (mesenchymal-epithelial transition factor) receptor tyrosine kinase is an exciting novel drug target in view of its key role in oncogenesis, as well as its association with disease prognosis in a number of malignancies. Several drugs targeting c-MET are currently showing promise in clinical trials and will hopefully validate positive observations from preclinical studies. The potential efficacy of these different therapeutic agents is expected to be influenced by the mechanism of aberr ...[more]

PMID: 22128288

Similar Datasets

Project description:Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton's tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and EGFR-family kinases. Zanubrutinib is more selective than ibrutinib for BTK versus EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, BLK and TEC. In addition, compared to ibrutinib, zanubrutinib has improved oral absorption and better target occupancy. Zanubrutinib demonstrated a lower incidence of off-target toxicities and reduced severity than ibrutinib. Moreover, zanubrutinib is similar to acalabrutinib, with less activity against TEC and ITK. The preliminary phase 1 results suggest that zanubrutinib has clinical activity and the drug is well tolerated in patients with B-cell lymphoid malignancies. Recent clinical trials have found it to demonstrate excellent efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM) and mantle cell lymphoma (MCL). In recent phase 3 studies, zanubrutinib was compared with ibrutinib in patients with relapsed/refractory (R/R) MW and RR CLL. In both trials, zanubrutinib was found to demonstrate clinically meaningful advantages in safety and tolerability over ibrutinib; in particular, it was associated with a lower risk of atrial fibrillation/flutter and major bleeding events. In the recent SEQUOIA study, comparing zanubrutinib with bendamustine and rituximab (BR) in patients with previously untreated CLL, zanubrutinib significantly improved progression-free survival versus BR, with an acceptable safety profile consistent with previous studies. Zanubrutinib also demonstrated good activity and tolerability in patients with R/R MCL, marginal zone lymphoma and follicular lymphoma. Trials examining the efficacy and safety of the combination of zanubrutinib with obinutuzumab venetoclax and other drugs are ongoing. This review summarizes the clinical efficacy and safety of zanubrutinib in lymphoid malignancies.

Project description:BackgroundSeveral technology-assisted aids are available to help blind and visually impaired people perform their daily activities. The current research uses the state-of-the-art technology to enhance the utility of traditional navigational aids to produce solutions that are more reliable. In this regard, a white cane is no exception, which is supplemented with the existing technologies to design Electronic Travel Aids (ETAs), Electronic Orientation Aids (EOAs), and Position Locator Devices (PLDs). Although several review articles uncover the strengths and limitations of research contributions that extend traditional navigational aids, we find no review article that covers research contributions on a technology-assisted white cane. The authors attempt to fill this literature gap by reviewing the most relevant research articles published during 2010-2017 with the common objective of enhancing the utility of white cane with the existing technology.MethodsThe authors have collected the relevant literature published during 2010-17 by searching and browsing all the major digital libraries and publishers' websites. The inclusion/exclusion criteria were applied to select the research articles that are relevant to the topic of this review article, and all other irrelevant papers were excluded. Among the 577 (534 through database searching and 43 through other sources) initially screened papers, the authors collected 228 full-text articles, which after applying exclusion/inclusion criteria resulted in 36 papers that were included in the evaluation, comparison, and discussion. This also includes research articles of commercially available aids published before the specified range.ResultsThe findings show that the research trend is shifting towards developing a technology-assisted white cane solution that is applicable in both indoor and outdoor environments to aid blind users in navigation. In this regard, exploiting smartphones to develop low-cost and user-friendly navigation solution is among the best research opportunities to explore. In addition, the authors contribute a theoretical evaluation framework to compare and evaluate the state-of-the-art solutions, identify research trends and future directions.DiscussionResearchers have been in the quest to find out ways of enhancing the utility of white cane using existing technology. However, for a more reliable enhancement, the design should have user-centric characteristics. It should be portable, reliable, trust-worthy, lightweight, less costly, less power hungry, and require minimal training with special emphasis on its ergonomics and social acceptance. Smartphones, which are the ubiquitous and general-purpose portable devices, should be considered to exploit its capabilities in making technology-assisted white cane smarter and reliable.

Project description:Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary brain tumor associated with poor prognosis and resistance to therapy, remains a significant challenge. Receptor tyrosine kinases (RTKs) are critical during development and in adulthood. Dysregulation of RTKs through activating mutations and gene amplification contributes to many human cancers and provides attractive therapeutic targets for treatment. Under physiological conditions, the Met RTK, the hepatocyte growth factor/scatter factor (HGF/SF) receptor, promotes fundamental signaling cascades that modulate epithelial-to-mesenchymal transition (EMT) involved in tissue repair and embryogenesis. In cancer, increased Met activity promotes tumor growth and metastasis by providing signals for proliferation, survival, and migration/invasion. Recent clinical genomic studies have unveiled multiple mechanisms by which MET is genetically altered in GBM, including focal amplification, chromosomal rearrangements generating gene fusions, and a splicing variant mutation (exon 14 skipping, METex14del). Notably, MET overexpression contributes to chemotherapy resistance in GBM by promoting the survival of cancer stem-like cells. This is linked to distinctive Met-induced pathways, such as the upregulation of DNA repair mechanisms, which can protect tumor cells from the cytotoxic effects of chemotherapy. The development of MET-targeted therapies represents a major step forward in the treatment of brain tumours. Preclinical studies have shown that MET-targeted therapies (monoclonal antibodies or small molecule inhibitors) can suppress growth and invasion, enhancing the efficacy of conventional therapies. Early-phase clinical trials have demonstrated promising results with MET-targeted therapies in improving overall survival for patients with recurrent GBM. However, challenges remain, including the need for patient stratification, the optimization of treatment regimens, and the identification of mechanisms of resistance. This review aims to highlight the current understanding of mechanisms underlying MET dysregulation in GBM. In addition, it will focus on the ongoing preclinical and clinical assessment of therapies targeting MET dysregulation in GBM.

Dataset Information

Future directions in the evaluation of c-MET-driven malignancies.

Publications

Future directions in the evaluation of c-MET-driven malignancies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets